Early Amivantamab Experience and Subcutaneous Dosing in COPERNICUS

Amanda Edmond, PA-C, of Banner MD Anderson Cancer Center at Banner Gateway Medical Center, opens this Oncology Nursing News Translating Trials discussion by revisiting the early experience with intravenous amivantamab plus lazertinib in patients with EGFR-mutated non-small cell lung cancer, when infusion-related reactions and rash defined the first cycles. She then explains how subcutaneous dosing has been "a game changer" for these patients. Coming in for an injection instead of an all-day infusion, and returning just once a month after the first cycle, is "very palatable to patients," she says, adding that it means "a lot less time in clinic" and "much less time in an infusion chair." That time savings also frees nursing staff for other patients. Edmond describes COPERNICUS as a pragmatic trial combining subcutaneous dosing, venous thromboembolism prophylaxis, and skin care prophylaxis. Early data show infusion-related reactions falling from about 63% in MARIPOSA to about 0.9%, with prophylactic skin care reducing significant dermatitis.